NMDA Receptor Modulation for the Treatment of Bipolar I Disorder — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder — Stella

Home/Bipolar I Disorder/

View on ClinicalTrials.gov

Recruiting

Back to Bipolar I Disorder trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Taiwan

Department of Psychiatry, China Medical University Hospital, Taichung

Key details

Phase

Safety & dosing

Sponsor

China Medical University Hospital

Collaborators

National Science and Technology Council

Enrollment target

~90 participants

Started

October 2023

Primary completion

November 2027

Age range

18 Years – 65 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.